A Study of JMT203 in Patients With Cancer Cachexia

[...] articipate in the study and sign the informed consent form; Inclusion Criteria: Age ≥ 18 years old; Voluntarily participate in the study and sign the informed consent form; Malignant solid tumors confirmed histologically or cytologic [...] ession within 28 days prior to the first drug administration: Dose escalation ，and expansion phase (Phase Ia): Thethe investigator predictsestimates that therethe participant will benot norequire needa switch to changeanother theanticancer anti-tumor treatment regimentherapy due to disease progression withinduring the first dosingtreatment cycle (21 days). For the [...] [...]

Phase Ia: The PD indicators include β-hydroxybutyric acid. Phase Ia: Average change in body weight from baseline at each assessment timepoint within 12 weeks. Phase IbII: Average change in the skeletal muscle index (SMI) of the t [...] computed tomography (CT), from baseline to 12 weeks. Phase IbII: Average change in the severity of anorexia (based on the F [...] CT-A/CS]) from baseline to each assessment timepoint. Phase IbII: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs). Phase IbII: Blood concentration of JMT203; Phase Ib: PD indicators include β-hydroxybutyric acid. P [...] [...]

[...] study of JMT203 in patients with cancer cachexia, and Phase IbII, which is a cohortmulticenter, randomized, double-expansionblind, placebo-controlled clinical study of JMT203 in the same patient population. The phase II stage includes three cohorts: Cohort A (participants with colorectal cancer cachexia), Cohort B (participants with pancreatic cancer cachexia), and Cohort C (participants with cachexia from other solid tumors) . The primary objectives of Phase Ia are to assess the safety/ [...] he recommended dose for expansion (RDE) of JMT203. In Phase IbII, the primary objectives include evaluating [...] [...]